Startup Dossier
Brink Therapeutics
Biotech startup developing programmable recombinase-based genome editing technology that enables precise insertion of long DNA sequences without double-strand breaks, offering a safer and more efficient alternative to CRISPR-Cas9 for cell and gene therapies.
active
Typestartup
SectorBioTech
LocationParis
About
Biotech startup developing programmable recombinase-based genome editing technology that enables precise insertion of long DNA sequences without double-strand breaks, offering a safer and more efficient alternative to CRISPR-Cas9 for cell and gene therapies.
Structural DNA
Legal Name
Brink Therapeutics
SIREN
933242950
Founders & Team
Funding Lineage
Seed
Kurma Partners (Lead)
€3.5M
Apr 2025